Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgery

Tobias Boch,Nikolaj Frost,Linna Sommer,Tobias R. Overbeck, Christoph T. Michaeli,Chrisoph J. Szuszies,Lisa-Marie Rieckmann,Niklas Beumer,Charles D. Imbusch,Hauke Winter, Michael Thomas,Julia Roeper,Melanie Janning,Frank Griesinger,Martin Wermke,Sonja Loges

Lung Cancer（2022）

引用 3|浏览2

暂无评分

摘要

•NSCLC patients with oligometastastic disease benefit from locally ablative and systemic therapy.•Neoadjuvant immunotherapy results in high pCR and MPR rates.•Neoadjuvant immunotherapy is a promising therapeutic concept for oligometastastic disease.

查看译文

关键词

Non-small cell lung cancer,Immunotherapy,Oligometastatic disease,Neoadjuvant therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要